secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0001104659-25-072992
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen reports Q2 2025 results; cash $27.3M; initiates OCU410ST Phase 2/3 trial
-------------------------------------------------------------------------------

- Cash, cash equivalents and restricted cash $27.3M as of June 30, 2025, down from $58.8M at Dec 31, 2024; cash runway into Q1 2026.
- Net loss $0.05 per share for Q2 2025, compared to $0.06 per share in Q2 2024; total operating expenses $15.2M.
- Initiated dosing in Phase 2/3 GARDian3 trial for OCU410ST (Stargardt disease) after FDA clearance; received Rare Pediatric Disease Designation.
- Signed binding term sheet for exclusive Korean rights to OCU400 with up to $11M in upfront and milestone payments.
- Announced planned reverse merger of OrthoCellix with Carisma to spin off NeoCart, with OrthoCellix valued at $135M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/0001104659-25-072992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/tm2522209d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer